Rachel McMinn

Chief Strategy Officer, Intercept Pharmaceuticals.

Companies

Neurogene Inc.Board member Dec 26, 2023 to now¹
Neurogene Inc.Chief executive officer Dec 26, 2023 to now¹
Intercept PharmaceuticalsChief Strategy Officer May 2, 2014 to Oct 4, 2017²

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

Neurogene Inc. NGNE1,344,307 shares³$32.1M at $23.89Mar 26, 2026

As of each latest filing. The line shows shares held over time.

Recent filings

Mar 26, 2026Sold 3,352 shares at $22.07 of Neurogene Inc.³
Feb 20, 2026Granted 25,900 shares of Neurogene Inc.⁴
Mar 26, 2025Granted 23,900 shares of Neurogene Inc.⁵
Nov 22, 2024Bought 47,500 shares at $20.40 of Neurogene Inc.⁶

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARNeurogene Inc., Board member
2
SEC EDGARIntercept Pharmaceuticals, Chief Strategy Officer
3
SEC EDGARNeurogene Inc. shares after the filing of Mar 26, 2026
4
SEC EDGARForm 4 filed Feb 24, 2026
5
SEC EDGARForm 4 filed Mar 28, 2025
6
SEC EDGARForm 4 filed Nov 25, 2024